A New Biomarker Frontier: Phosphorylated α-Synuclein in Skin Biopsies
In a recent correspondence in The Lancet Neurology, authors have responded to comments regarding their review on the detection of phosphorylated α-synuclein in skin tissue. This exchange highlights the ongoing validation and discussion of a novel diagnostic method for synucleinopathies, such as Parkinson’s disease. The technique represents a shift from traditional cerebrospinal fluid (CSF) analysis towards a less invasive, cutaneous biopsy, aiming to identify pathological protein aggregates with high specificity through advanced immunoassays and molecular diagnostics.
Why it might matter to you: For professionals in laboratory medicine, this development underscores the expanding role of specialized immunoassays and tissue-based molecular diagnostics beyond conventional fluid samples. It signals a potential new stream of pre-analytical and analytical considerations for clinical chemistry and pathology labs, from specimen collection protocols for skin biopsies to the establishment of rigorous quality control and reference ranges for this novel assay. Its adoption could influence diagnostic algorithms for neurological disorders, placing the laboratory at the center of earlier and less invasive patient workups.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
